-OP \$115.00 7815805

TRADEMARK ASSIGNMENT

Electronic Version v1.1 Stylesheet Version v1.1

SUBMISSION TYPE:	CORRECTIVE ASSIGNMENT	
NATURE OF CONVEYANCE:	Corrective Assignment to correct the wrong serial no. 78/153053 ROOM ONE CONTEMPORARY LIVING. The correct no. is 78/158053 TRANSCEPTOR. previously recorded on Reel 003090 Frame 0731. Assignor(s) hereby confirms the SECURITY INTEREST.	

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
Syntonix Pharmaceuticals, Inc.		04/30/2005	CORPORATION: DELAWARE

RECEIVING PARTY DATA

Name:	The Bay City Capital Fund III, L.P., as agent
Street Address:	750 Battery Street
Internal Address:	Suite 600
City:	San Francisco
State/Country:	CALIFORNIA
Postal Code:	94111
Entity Type:	LIMITED PARTNERSHIP: DELAWARE

PROPERTY NUMBERS Total: 4

Property Type	Number	Word Mark
Serial Number:	78158053	TRANSCEPTOR
Serial Number:	78449605	SYNTONIX
Serial Number:	78457079	SYNFUSION
Serial Number:	78153053	ROOM ONE CONTEMPORARY LIVING

CORRESPONDENCE DATA

Fax Number: (617)526-5000

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 6175266448

Email: janey.davidson@wilmerhale.com
Correspondent Name: Michael J. Bevilacqua, Esquire

Address Line 1: Wilmer Cutler Pickering Hale and DorrLLP

Address Line 2: 60 State Street

TRADEMARK REEL: 003341 FRAME: 0766

900052467

Address Line 4: Boston, MASSACHUSETTS 02109		
NAME OF SUBMITTER:	Michael J. Bevilacqua	
Signature:	/michael j. bevilacqua/	
Date:	07/05/2006	
Total Attachments: 7 source=assignment correction transceptor#page1.tif source=assignment correction transceptor#page2.tif source=assignment correction transceptor#page3.tif source=assignment correction transceptor#page4.tif source=assignment correction transceptor#page5.tif source=assignment correction transceptor#page6.tif source=assignment correction transceptor#page7.tif		

TRADEMARK REEL: 003341 FRAME: 0767

	OMB Collection 0651-0027 (exp. 6/30/20 05 - 17	-2005 United States Patent and Trademark Office
	To the Director of the U. S. Patent and 10290	6026 cuments or the new address(es) below.
	1. Name of conveying party(ies): Syntonix Pharmaceuticals, Inc.	2. Name and address of receiving party(ies) Additional names, addresses, or citizenship attached?
SP-91-5	Individual(s) Association General Partnership Limited Partnership Corporation- State: Delaware Other Citizenship (see guidelines) Additional names of conveying parties attached? Yes No. 3. Nature of conveyance //Execution Date(s): Execution Date(s) April 30, 2005 Assignment Merger Security Agreement Change of Name Other 4. Application number(s) or registration number(s) and A. Trademark Application No.(s) 78/153,053; 78/457,079;	General Partnership Citizenship X Limited Partnership Citizenship Delawaye Corporation Citizenship Citizenship Cither Citizenship If assignee is not domiciled in the United States, a domestic representative designation is attached: Yes No (Designations must be a separate document from assignment)
	78/449,605 C. Identification or Description of Trademark(s) (and Filing	Additional sheet(s) attached? Yes No No Date if Application or Registration Number is unknown):
	5. Name & address of party to whom correspondence concerning document should be mailed: Name: Elizabeth J. Burns	6. Total number of applications and registrations involved:
	Street Address: 233 S. Wacker Drive Suite 5800	7. Total fee (37 CFR 2.6(b)(6) & 3.41) \$ 90.00 Authorized to be charged by credit card Authorized to be charged to deposit account Enclosed
	City: Chicago State: Illinois Zip: 60606 Phone Number: 312/876-7629 Fax Number: 312/993-9767 Email Address: elizabeth.burns@lw.com	8. Payment Information: a. Credit Card Last 4 Numbers Expiration Date b. Deposit Account Number Authorized User Name
05/18/2005 D 01 FC:8521 02 FC:8522	Documents of the Precorded (Including cover sheet Mail Stop Assis Control of the Precorded	May 13, 2005 Date Total number of pages including cover 7 sheet, attachments, and document: should be faxed to (703) 306-5995, or mailed to: the USPTC P.O. Box 1450, Alexandria, VA 22313-1450
03 FC:8523	120.00 OP	A

TRADEMARK REEL: 003090 FRAME: 0731 **TRADEMARK**

SUPPLEMENT TO TRADEMARK SECURITY AGREEMENT

THIS SUPPLEMENT TO TRADEMARK SECURITY AGREEMENT (this "Supplement"), dated as of April __, 2005, made by Syntonix Pharmaceuticals, Inc., a Delaware corporation ("Grantor") to the Trademark Security Agreement, dated as of May 12, 2004 (as amended, supplemented or otherwise modified from time to time, the "Trademark Security Agreement") between Grantor and The Bay City Capital Fund III, L.P., as agent ("Agent") for Venrock Associates, Venrock Associates II, L.P., Venrock Entrepreneurs Fund III, L.P., Alta BioPharma Partners II, L.P., Alta Embarcadero BioPharma Partners II, LLC, AEOW 2000, LP, The AFB Fund LLC, A. M. Pappas Life Science Ventures II, L.P., Biomedicine, L.P., The Bay City Capital Fund III, L.P., in its capacity as a lender, and The Bay City Capital Fund III Co-Investment Fund L.P. (the "Lenders"). All capitalized terms not defined herein shall have the collective meanings ascribed to them in the Trademark Security Agreement or the Security Agreement (as defined below).

WITNESSETH:

WHEREAS, pursuant to that certain Note and Warrant Purchase Agreement dated as of May 12, 2004 by and among Grantor and Lenders (including all annexes, exhibits or schedules thereto, and as from time to time amended, restated, supplemented or otherwise modified, the "Purchase Agreement"), Lenders agreed to purchase notes and warrants from the Grantor (collectively referred to herein as "Securities");

WHEREAS, as a condition to the Lenders purchase of the Securities as provided for in the Purchase Agreement, the Grantor and Agent have entered into a Security Agreement, dated as of May 12, 2004 (including all annexes, exhibits or schedules thereto, as from time to time amended, restated, supplemented or otherwise modified, the "Security Agreement");

WHEREAS, pursuant to Section 10(b) of the Security Agreement, Grantor is obligated to provide Agent prompt written notice upon filing any application for the registration of any trademark with the United States Patent and Trademark Office;

WHEREAS, pursuant to <u>Section 10(b)</u> of the Security Agreement, Grantor is obligated to execute and deliver any and all trademark security agreements as Agent may request to evidence Agent's Lien on such trademarks or trademark applications; and

WHEREAS, the Grantor has filed an application for the registration of Trademarks as set forth on Schedule 1 attached hereto and desires, pursuant to Section 10(b) of the Security Agreement, to grant to Agent, on behalf of itself and Lenders, a continuing first priority security interest in such Trademarks.

NOW, THEREFORE, IT IS AGREED:

1. Addition to Schedule of Trademark Security Agreement. The information set forth on Schedule 1 attached hereto is hereby added to Schedule I of the Trademark Security Agreement. Grantor hereby grants to Agent, on behalf of itself and Lenders, a continuing first

1

CH\751440.2

TRADEMARK
REEL: 003090 FRAME: 0732
TRADEMARK

priority security interest in all of Grantor's right, title and interest in, to and under the Trademarks referred to on Schedule 1 attached hereto, all reissues, continuations or extensions thereof and all products and proceeds thereof, including, without limitation, any claim by Grantor against third parties for past, present or future infringement or dilution of any such Trademark.

- 2. <u>Counterparts</u>. This supplement may be executed by one or more of the parties hereto on any number of separate counterparts (including by facsimile transmission), and all of said counterparts taken together shall be deemed to constitute one and the same document.
- 3. Governing Law. This supplement shall be governed by, and construed and interpreted in accordance with, the law of the State of Delaware (without giving effect to principles of conflicts of laws).

CH\751440.2

TRADEMARK
REEL: 003090 FRAME: 0733
TRADEMARK

IN WITNESS WHEREOF, Grantor has caused this Supplement to Trademark Security Agreement to be executed and delivered by its duly authorized officer as of the date first set forth above.

SYNTONIX PHARMACEUTICALS, INC., as Grantor

Name: GAKAO BOHUN

Title: PRESIDENT 4 CER

[Signature Page to Supplement to Trademark Security Agreement]

CH\751440

TRADEMARK
REEL: 003090 FRAME: 0734
TRADEMARK

ACCEPTED AND ACKNOWLEDGED BY:

THE BAY CITY CAPITAL FUND III, L.P., as Agent for the Lenders

By: Bay City Capital Management III LLC

Its: General Partner

By: Bay City Capital LLC

Its: Manager

Name: Carl Goldfischer, MD Title: Managing Director

[Signature Page to Supplement to Trademark Security Agreement]

CH\751440

TRADEMARK **REEL: 003090 FRAME: 0735 TRADEMARK**

SCHEDULE 1

TRADEMARK APPLICATIONS

MARK APP. NO. FILING DATE

TRANSCEPTOR	78/153,053	
SYNFUSION	78/457,079	July 27, 2004
SYNTONIX	78/449,605	July 13, 2004

Sch.I-1

CH\751440.2

RECORDED: 05/16/2005

RECORDED: 07/05/2006

TRADEMARK
REEL: 003090 FRAME: 0736
TRADEMARK